Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Holden, SN
Ryan, E
Kearns, A
Holmgren, E
Hurwitz, H
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Duke Univ, Ctr Med, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：259S / 259S
页数：1
相关论文
共 50 条
  • [1] VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Santini, D.
    Bencardino, K.
    Manzoni, M.
    Falcone, A.
    Graziano, F.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 357 - 357
  • [2] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [3] Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC).
    Mass, RD
    Sarkar, S
    Holden, SN
    Hurwitz, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [4] ADVERSE EVENTS (AES) ASSOCIATED WITH BEVACIZUMAB (BV) IN OLDER PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Shankaran, V.
    Mummy, D.
    Koepl, L.
    Blough, D.
    Yim, Y. M.
    Yu, E.
    Ramsey, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 203 - 203
  • [5] Functional SNPs in vascular endothelial growth factor (VEGF-A) and overall survival (OS) in bevacizumab-treated patients with metastatic colorectal cancer (mCRC).
    Murphy, Janet E.
    Liebman, Hannah M.
    Zhou, Qian
    Bote, Josiah T.
    Daskalova, Anastassia
    Hooshmand, Susanne M.
    Ryan, David P.
    Kulke, Matthew
    Christiani, David C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.
    Weickhardt, A. J.
    Williams, D.
    Lee, C.
    Simes, J.
    Murone, C.
    Wilson, K.
    Cummins, M.
    Asadi, K.
    Price, T. J.
    Mariadason, J.
    Tebbutt, N. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [8] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 250 - 251
  • [9] Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.
    Mooi, Jennifer
    Chong, Geoffrey
    Brown, Stephen
    Wong, Rachel
    Price, Timothy Jay
    Skrinos, Effie
    Tebbutt, Niall C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Possibile role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results
    Silvestris, N.
    Azzariti, A.
    Porcelli, L.
    Quatrale, A. E.
    Paradiso, A.
    Colucci, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345